Immunotherapy shows clinical benefit in relapsed transplant recipients

A multicenter phase 1 trial of the immune checkpoint blocker ipilimumab found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation, according to investigators from Dana-Farber Cancer Institute, who developed and lead the study. The study reported at the American Society of Hematology annual meeting is the first in which ipilimumab was given in multiple doses over an extended time period, the researchers said.

http://ift.tt/1616tCb